Research shows that for every 5,000 to 10,000 compounds entering the pipeline, only one will make it to market. As such, the responsibility falls on pharmaceutical and biotechnology companies to cut costs, shorten timelines, and increase the probability that their compound will be one of the few to succeed.
Developing a comprehensive drug development strategy is key to increasing a drug’s likelihood of making it to market. In our upcoming webcast on Wednesday, March 26, 2014 @ 11:30 am ET, you’ll learn how issues such as slow study enrollment, trial designs that do not meet regulatory expectations, or prohibitively expensive raw materials can be more easily managed or, in some cases, avoided altogether if development starts with a comprehensive strategy.
The interactive discussion will cover:
- Three foundational questions to consider that form a base for building specific sections of your comprehensive drug development strategy
- Best practices for strategic planning in five key areas:
- Preclinical/nonclinical development
- Clinical development
- Other (i.e., IP, reimbursement, and marketing)
- Brenda Fielding, Executive Vice President, Regulatory Affairs, Clinipace Worldwide
- Monika Frey, Vice President, Global Clinical Operations, Clinipace Worldwide
- Nik Burlew, Vice President, Quality Systems, Clinipace Worldwide
Register today to reserve your spot. And be on the lookout for an accompanying eBook within the next few weeks!